. Author manuscript; available in PMC: 2012 Sep 25.

Published in final edited form as: Toxicol Appl Pharmacol. 2010 Aug 20;249(1):47–54. doi: 10.1016/j.taap.2010.08.013

Table III.

Non-dermatological clinical findings in the study populations

Parameters	Unexposed Group (N=41)		Exposed without skin lesion group (N=16)		Exposed with skin lesion group (N=34)
	N (%)	OR (Ref)	N (%)	OR (95%CI)^a	N (%)	OR (95%CI)^a	OR (95%CI)^b
Eye Diseases
Present	2 (4.88)	1.0	5 (31.25)	8.86 (1.51–52.12)	22 (64.71)	37.75 (7.32–174.60)	4.03 (1.13–14.36)
Absent	39 (95.12)	1.0	11 (68.75)	8.86 (1.51–52.12)	12 (35.29)	37.75 (7.32–174.60)	4.03 (1.13–14.36)
Respiratory Illness
Present	1 (2.44)	1.0	4 (25.00)	13.33 (1.36–130.99)	8 (23.53)	12.31 (1.45–104.32)	0.92 (0.23–3.68)
Absent	40 (97.56)	1.0	12 (75.00)	13.33 (1.36–130.99)	26 (76.47)	12.31 (1.45–104.32)	0.92 (0.23–3.68)
Peripheral Neuropathy
Present	1 (2.44)	1.0	4 (25.00)	13.33 (1.36–130.99)	20 (58.82)	57.14 (7.00–466.21)	4.29 (1.14–16.08)
Absent	40 (97.56)	1.0	12 (75.00)	13.33 (1.36–130.99)	14 (41.18)	57.14 (7.00–466.21)	4.29 (1.14–16.08)

OR and 95% CI calculated for with reference to Unexposed group;

OR and 95% CI calculated for with reference to exposed without skin lesion group.